Gina Mauro

Results from the phase 2 KEYNOTE-B61 trial showed prolonged survival in patients with advanced non–clear cell renal cell carcinoma.

Neoadjuvant camrelizumab plus chemotherapy may hold promise as a standard of care in locally advanced esophageal squamous cell carcinoma, according to Yin Li, MD.

Investigators of a phase 1 trial identify no safety signals with Orca-Q in the haploidentical stem cell transplantation setting.

The combination of pelabresib plus ruxolitinib shows improvement in hemoglobin response in the MANIFEST-2 trial, supporting a potential shift in the future treatment of patients with JAK inhibitor–naive myelofibrosis.

No patients with myelodysplastic syndrome have any grade 3 or higher acute graft-versus-host disease following treatment with Orca-T in a phase 1b study.

Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.

Data from the phase 2 DESTINY-PanTumor02 trial support trastuzumab deruxtecan as a potential treatment for patients with gynecologic HER2-expressing tumors that have progressed on prior therapy.

Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.

Selpercatinib significantly improved efficacy in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer.

Many patients with relapsed/refractory multiple myeloma appear to remain on treatment with mezigdomide-based regimens for more than 1 year, according to Albert Oriol, PhD.

Patients with metastatic renal cell carcinoma, and those who have been pretreated with immune checkpoint inhibitors and are naive, saw a benefit with lenvatinib plus pembrolizumab.

Data from the phase 3 CONTACT-03 trial highlight the necessity of randomized, prospective assessment of re-challenge with checkpoint inhibitors in renal cell carcinoma, according to an expert from Dana-Farber Cancer Institute.

Patients with folate receptor alpha (FRα)–high, platinum-resistant ovarian cancer experienced progression-free survival benefit following treatment with mirvetuximab soravtansine-gynx.

Obecatagene autoleucel also appears to result in a high rate of minimal residual disease negativity in a population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Simple hysterectomy may become the new standard of care for patients with low-risk, early-stage cervical cancer, according to an expert from Université Laval in Quebec City, Canada.

A positive R0 resection rate helped to confirm the noninferiority of minimally invasive distal pancreatectomy compared with open distal pancreatectomy in those with resectable pancreatic cancer.

ALLO-316 has some “unique features” that may make it an “attractive” treatment option for those with kidney cancer, according to an expert from The University of Texas MD Anderson Cancer Center.

89Zr-DFO-girentuximab improves sensitivity and specificity in identifying clear cell kidney cancer compared with any metric to date, according to an expert from the University of California, Los Angeles.

Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.

Patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor experienced durable responses up to 48 weeks with momelotinib.

Blinatumomab plus consolidation chemotherapy produced a 58% reduction in the risk of death vs consolidation chemotherapy alone in patients with MRD-negative B-cell acute lymphoblastic leukemia.

Among patients with paroxysmal nocturnal hemoglobinuria, crovalimab yielded stable rates of hemolysis control and transfusion avoidance in the phase 3 COMMODORE trial.

Patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia, chronic phase, or acute phase who are resistant to tyrosine kinase inhibitors were found to show a clinical benefit with olvermbatinib.

Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.

Transplants from a matched sibling donor were superior to haploidentical stem cell transplant in terms of 2-year survival in patients with relapsed/refractory acute lymphoblastic leukemia.

Although canakinumab, pembrolizumab, and chemotherapy did not lead to an improvement in survival vs the placebo cohort, it may still have benefit in certain subgroups of patients with previously untreated locally advanced or metastatic non–small cell lung cancer.

Patients with advanced or recurrent uterine serous carcinoma derived promising benefit from treatment with ZN-c3.

Updated data from the phase 1/2 CodeBreaK 100 trial of sotorasib provide the longest follow-up of a KRAS G12C inhibitor in non–small cell lung cancer.

The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.